Hims & Hers Stock: A High-Stakes Balancing Act

The telehealth provider Hims & Hers finds itself navigating a complex and precarious situation. As the company aggressively expands its service portfolio with a new laboratory offering, it simultaneously faces a wrongful death lawsuit that threatens to destabilize its stock. This tension is further amplified by insider stock sales and a deeply divided analyst community, leaving investors to ponder whether the stock holds untapped potential or is primarily a risk-laden bet.

Wall Street’s Divided Opinion

Market experts are sending conflicting signals regarding the future of Hims & Hers, reflecting the company’s current dichotomy of opportunity and peril.

• Morgan Stanley maintains an “Equal-weight” rating, expressing concern over slowing growth in the company’s core business segments.
• Leerink Partners presents a more optimistic view, having raised its price target on the stock. Their position is that the company delivered a solid performance in the last quarter, despite ongoing challenges.
• Needham and Jefferies both advise a “Hold.” Their primary apprehension stems from major pharmaceutical companies slashing prices for GLP-1 medications. This aggressive pricing could severely undermine the competitive pricing advantage that has been a key part of Hims & Hers’ strategy.

The company’s recent financial performance adds to the mixed picture. While Hims & Hers surpassed revenue expectations for the third quarter of 2025, it concurrently narrowed its full-year guidance. More alarmingly, key performance indicators such as app downloads and web traffic have declined year-over-year, signaling potential headwinds in acquiring new customers. This places immense pressure on new product initiatives to deliver significant growth.

Should investors sell immediately? Or is it worth buying Hims & Hers?

Legal Peril and Insider Transactions

Compounding the strategic challenges is a significant legal threat. A recently filed lawsuit alleging negligent homicide introduces substantial litigation risk, which has the potential to dramatically increase stock price volatility.

Investor confidence is also being tested by the actions of corporate insiders. Director Soleil Boughton recently divested 2,637 shares. Transactions of this nature are closely monitored by the market and often contribute to a climate of uncertainty, rather than fostering trust.

Quest Diagnostics Partnership as a Growth Catalyst

In a bold move to counter these challenges, Hims & Hers has launched a new service called “Labs” in partnership with Quest Diagnostics. The strategic objective is to move beyond the traditional scope of telehealth by offering preventative care laboratory services. This initiative is designed to attract an entirely new customer demographic, providing a potential catalyst to boost both revenue and user numbers in the short to medium term. The success of this foray into the laboratory testing market is now more critical than ever for the company’s growth narrative.